Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
ACXP•Expense drivers
- R&D spending — Higher research and development expenses were driven by increased manufacturing and consulting costs for a new recurrent CDI trial program.
- Lower G&A costs — General and administrative expenses decreased mainly due to reduced professional fees, legal costs, and share-based compensation.
Outlook and analyst coverage
The company did not provide specific financial guidance for the current or future periods.
The current average analyst rating on the shares is "buy", with 3 "strong buy" or "buy" recommendations, no "hold" and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy". Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $10.00, about 575.7% above its August 13 closing price of $1.48.
